Results 171 to 180 of about 40,773 (330)
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.
New England Journal of Medicine, 2016 BACKGROUND Pharmacologic inhibitors of proprotein convertase subtilisin-kexin type 9 (PCSK9) are being evaluated in clinical trials for the treatment of cardiovascular disease.
B. Ference +11 more
semanticscholar +1 more source
A whole-body mathematical model of cholesterol metabolism and transport [PDF]
arXivCardiovascular diseases are the leading cause of death. Increased levels of plasma cholesterol are consistently associated with an increased risk of cardiovascular disease. As a result, it is imperative that studies are conducted to determine the best course of action to reduce whole-body cholesterol levels.
arxiv
Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype [PDF]
, 2004 Kara N. Maxwell, Jan L. Breslow
openalex +1 more source
Innovative pharmacotherapy for hepatic metabolic and chronic inflammatory diseases in China
British Journal of Pharmacology, EarlyView.Abstract Liver disease constitutes a significant global health concern, particularly in China where it has distinctive characteristics. China grapples with a staggering 300 million cases, predominantly due to hepatitis B and metabolic non‐alcoholic fatty liver disease. Additionally, hepatocellular carcinoma has become a prevalent which is a lethal type
Feng Zhang +5 more
wiley +1 more source
Apolipoprotein B100 Metabolism in Autosomal-Dominant Hypercholesterolemia Related to Mutations inPCSK9 [PDF]
, 2004 Khadija Ouguerram +8 more
openalex +1 more source
PCSK9 and Lipoprotein(a) [PDF]
Circulation Research, 2016 Proprotein convertase subtilisin kexin type 9 (PCSK9) has rapidly become a focus of intensive investigation worldwide because of its linkage to multiple clinically important facets of hepatic lipoprotein metabolism. To facilitate secretion and proper folding, the zymogen pro-PCSK9 must undergo autocatalytic cleavage.
openaire +3 more sources
Lactate and Lactylation in AKI‐to‐CKD: Epigenetic Regulation and Therapeutic Opportunities
Cell Proliferation, EarlyView.ABSTRACT Lactate is not only a byproduct of glycolysis, but is also considered an energy source, gluconeogenic precursor, signalling molecule and protein modifier during the process of cellular metabolism. The discovery of lactylation reveals the multifaceted functions of lactate in cellular metabolism and opens new avenues for lactate‐related research.
Yi Hou +7 more
wiley +1 more source
Forum Médical Suisse ‒ Swiss Medical Forum, 2017 Le praticien connaît la difficulté à traiter certaines hypercholestérolémies, tant pour atteindre les taux cibles de LDL-cholestérol que pour éviter des effets secondaires. Les inhibiteurs de PCSK9 sur la liste des spécialités dès juillet 2017 sont une nouvelle option thérapeutique pour abaisser le LDL-cholestérol de moitié.
Lyko, Christina +5 more
openaire +3 more sources
Diabetes, Obesity and Metabolism, EarlyView.Abstract Aims [D3,G40,K41.C16 diacid]exendin‐4 (acyl‐ExD3) and [F1,G40,K41.C16 diacid]exendin‐4 (acyl‐ExF1) are oppositely biased glucagon‐like peptide‐1 (GLP‐1) receptor agonists that preferentially promote β‐arrestin recruitment or G protein‐induced signalling, respectively.
Melanie Modder +9 more
wiley +1 more source